Literature DB >> 1884743

S-mephenytoin 4-hydroxylation in older Americans.

B G Pollock1, J M Perel, M Kirshner, L P Altieri, A L Yeager, C F Reynolds.   

Abstract

To examine whether a drug-metabolizing enzyme changes with normal aging, the S:R index of S-mephenytoin 4-hydroxylation was determined in 150, unmedicated elderly Americans (mean age 75.4). Ten (6.7%) were identified as categorically slow metabolizers (S:R ratios greater than or equal to .95). This increased incidence of slow metabolizers was accounted for by a significant and previously unreported, increased proportion of slow metabolizers among the black (18.5%) as compared to the white subjects (4.1%) (P = .017). There was no relationship found between S:R ratios and age or creatinine clearance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1884743     DOI: 10.1007/bf00279979

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

Review 1.  Inborn 'errors' of drug metabolism. Pharmacokinetic and clinical implications.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

2.  Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole.

Authors:  T Andersson; C Cederberg; G Edvardsson; A Heggelund; P Lundborg
Journal:  Clin Pharmacol Ther       Date:  1990-01       Impact factor: 6.875

3.  The effect of age upon liver volume and apparent liver blood flow in healthy man.

Authors:  H A Wynne; L H Cope; E Mutch; M D Rawlins; K W Woodhouse; O F James
Journal:  Hepatology       Date:  1989-02       Impact factor: 17.425

4.  Hepatic drug metabolism in female Fischer rats as a function of age.

Authors:  L E Rikans
Journal:  Drug Metab Dispos       Date:  1989 Jan-Feb       Impact factor: 3.922

5.  Age-associated stereoselective alterations in hexobarbital metabolism.

Authors:  M H Chandler; S R Scott; R A Blouin
Journal:  Clin Pharmacol Ther       Date:  1988-04       Impact factor: 6.875

6.  Benzodiazepines of long and short elimination half-life and the risk of hip fracture.

Authors:  W A Ray; M R Griffin; W Downey
Journal:  JAMA       Date:  1989-12-15       Impact factor: 56.272

Review 7.  Genetic polymorphism of S-mephenytoin hydroxylation.

Authors:  G R Wilkinson; F P Guengerich; R A Branch
Journal:  Pharmacol Ther       Date:  1989       Impact factor: 12.310

8.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.

Authors:  K Nakamura; F Goto; W A Ray; C B McAllister; E Jacqz; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

9.  Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.

Authors:  L Bertilsson; T K Henthorn; E Sanz; G Tybring; J Säwe; T Villén
Journal:  Clin Pharmacol Ther       Date:  1989-04       Impact factor: 6.875

10.  Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.

Authors:  P J Wedlund; W S Aslanian; C B McAllister; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1984-12       Impact factor: 6.875

  10 in total
  8 in total

1.  Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers.

Authors:  S Hägg; O Spigset; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

Review 2.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

3.  Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.

Authors:  H G Xie; R B Kim; C M Stein; G R Wilkinson; A J Wood
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

Review 4.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19.

Authors:  D A Flockhart
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

Review 6.  Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.

Authors:  L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447

7.  Effect of age, weight, and CYP2C19 genotype on escitalopram exposure.

Authors:  Yuyan Jin; Bruce G Pollock; Ellen Frank; Giovanni B Cassano; Paola Rucci; Daniel J Müller; James L Kennedy; Rocco Nicola Forgione; Margaret Kirshner; Gail Kepple; Andrea Fagiolini; David J Kupfer; Robert R Bies
Journal:  J Clin Pharmacol       Date:  2009-10-19       Impact factor: 3.126

8.  Population pharmacokinetics model for escitalopram in Chinese psychiatric patients: effect of CYP2C19 and age.

Authors:  Shujing Liu; Tao Xiao; Shanqing Huang; Xiaolin Li; Wan Kong; Ye Yang; Zi Zhang; Xiaojia Ni; Haoyang Lu; Ming Zhang; Dewei Shang; Yuguan Wen
Journal:  Front Pharmacol       Date:  2022-07-18       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.